Serum CA 125 levels are elevated in chronic heart failure and correlate with disease severity, suggesting potential utility as a biomarker for prognosis and clinical decision-making.
May inform HF prognosis; leaves open clinical adoption pending prospective validation.
It has been widely demonstrated that patients diagnosed with chronic heart failure present high levels of circulating neurohormones and inflammation markers which can secondarily induce an increase of the level of tumor markers such as CA 125, AFP, CEA, CA 15.3 or CA 19-9. This is a literature review regarding the benefits of determination of tumor markers serum levels in cases presenting chronic heart failure.
No takes yet. Share an insight, caveat, or question.
Bacalbașa et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: